Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459230 | 0.85 | CRHR1 (0.52) | CRHR1ALDH3A1ALDH1A3 | |
| SCHEMBL13459532 | 0.81 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL13459570 | 0.74 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL3288863 | 0.73 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL3209738 | 0.72 | CRHR1 (0.43) | CRHR1ALDH1A1GRM2 | |
| SCHEMBL13459227 | 0.70 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL13459730 | 0.69 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL3284887 | 0.68 | CSNK2A2 (0.41) | CRHR1ALDH3A1ALDH1A3ALDH1A1 | |
| SCHEMBL13459727 | 0.67 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL3287091 | 0.66 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1677791-A4 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | CRHR1 4/4885ALDH3A1 1202/4885ALDH1A3 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.